Fampridine (Fampyra®) in cases of multiple sclerosis (MS)

The National Health Care Institute carried out an assessment of the medicinal product fampridine (Fampyra®). Based on the outcomes of the assessment, the Executive Board of the National Health Care Institute advised the Minister not to include fampridine in the insured standard package.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.